Tanishima Yuichiro, Takahashi Keita, Nishikawa Katsunori, Ishikawa Yoshitaka, Yuda Masami, Tanaka Yujiro, Matsumoto Akira, Yano Fumiaki, Eto Ken
Division of Gastrointestinal Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan.
Esophagus. 2023 Oct;20(4):651-659. doi: 10.1007/s10388-023-01005-z. Epub 2023 Apr 21.
Neoadjuvant chemotherapy followed by surgery is Japan's most effective treatment modality for advanced thoracic esophageal squamous cell carcinoma. However, the prognosis is not as expected. This study aimed to examine prognostic factors in patients with pathologically ineffective neoadjuvant chemotherapy followed by surgery for esophageal squamous cell carcinoma.
We retrospectively analyzed patients who underwent neoadjuvant chemotherapy followed by curative esophagectomy for esophageal squamous cell carcinoma between December 2008 and July 2021. The patients were divided into the neoadjuvant chemotherapy effective group and the neoadjuvant chemotherapy ineffective group according to the pathological diagnosis. Clinicopathological data, prognosis, and recurrence were analyzed.
A total of 143 patients (121 males, 22 females; median age, 67 years) were included in this study. Of these, 34 patients were classified into the effective group and the remaining 109 patients were assigned to the ineffective group. The ineffective group had significantly worse overall survival and recurrence-free survival than the effective group (p = 0.0192 and p = 0.0070, respectively). In the ineffective group, multivariate analysis demonstrated that microscopic venous invasion was an independent prognostic factor for overall survival (hazard ratio 2.44; 95% confidence interval 1.13-5.30) and recurrence-free survival (hazard ratio 2.43; 95% confidence interval 1.24-4.73).
Microscopic venous invasion was associated with poor survival and cancer recurrence in the neoadjuvant chemotherapy ineffective group of patients who underwent esophagectomy for esophageal squamous cell carcinoma.
新辅助化疗后行手术是日本治疗晚期胸段食管鳞状细胞癌最有效的治疗方式。然而,预后并不理想。本研究旨在探讨食管鳞状细胞癌患者在接受病理上无效的新辅助化疗后行手术治疗的预后因素。
我们回顾性分析了2008年12月至2021年7月期间接受新辅助化疗后行根治性食管切除术治疗食管鳞状细胞癌的患者。根据病理诊断将患者分为新辅助化疗有效组和新辅助化疗无效组。分析临床病理数据、预后和复发情况。
本研究共纳入143例患者(男性121例,女性22例;中位年龄67岁)。其中,34例患者被分类为有效组,其余109例患者被分配到无效组。无效组的总生存期和无复发生存期明显比有效组差(分别为p = 0.0192和p = 0.0070)。在无效组中,多因素分析表明,显微镜下静脉侵犯是总生存期(风险比2.44;95%置信区间1.13 - 5.30)和无复发生存期(风险比2.43;95%置信区间1.24 - 4.73)的独立预后因素。
在接受食管鳞状细胞癌食管切除术的新辅助化疗无效组患者中,显微镜下静脉侵犯与生存率低和癌症复发相关。